none in 10, one in 8, two in 4, and three in 4. NHL was of
Introduction
The THP-COPBLM regimen consisted of six 3-week cycles of cyclophosphamide (CPM, 400 mg/m 2 ) and THP (40 mg/m 2 ) The recent introduction of potent multidrug chemotherapy administrated by intravenous infusion on day 1, vincristine regimens for the treatment of non-Hodgkin's lymphoma (NHL) (VCR, 1 mg/m 2 ; maximum dose, 2 mg) by intravenous injechas raised expectations of a high remission rate and a high tion on day 1. Prednisolone (PDN, 40 mg/m 2 ) and procarbazlong-term survival rate. 1, 2 Although elderly patients with NHL ine (PCZ, 100 mg/m 2 ) orally on days 1-10, and bleomycin are increasing in association with the growing elderly popu-(BLM, 10 mg per patient) by intravenous infusion on day 14. lation, such potent chemotherapy regimens are difficult to use Subcutaneous injection of recombinant human granulocyte on them because of their decreased organ reserve. Accordcolony-stimulating factor (G-CSF, 2 g/kg/day) was adminisingly, elderly patients have been excluded from many studies tered when the granulocyte count decreased to р1000/l, on potent chemotherapy regimens, including the third generand was discontinued when the white blood cell count ation regimens, and chemotherapy protocols appropriate for increased to у10 000/l. In patients aged 80 years and over, the elderly have not been investigated sufficiently.
the doses of CPM and THP were reduced to 70%. In patients In the present study, we used the THP-COPBLM having renal dysfunction (creatinine Ͼ1.5 mg/dl) or liver dys-(pirarubicin, cyclophosphamide, vincristine, prednisone, function (total bilirubin Ͼ1.5 mg/dl), the doses of THP and bleomycin and procarbazine) regimen to treat elderly patients CPM were reduced to 70%. If pulmonary function was abnorwith NHL. One of its components is a new anthracycline, mal (PaO 2 Ͻ60 mmHg or pulmonary carbon monoxide diffuspirarubicin (tetrahydropyranyladriamycin, THP), which is less ing capacity, % DLCO Ͻ70%), BLM was withdrawn from the toxic than doxorubicin (DXR line was given as a substitute for THP.
Statistical analysis
Therapeutic efficacy was evaluated after at least six cycles (unless the disease was advanced) according to the criteria for evaluation of the efficacy of Solid Cancer Chemotherapy 7 were used to assess responses. Survival rates and remission rate curves were calculated according to the Kaplan-Meier method. 8 WHO criteria 4 were used to define adverse effects.
Results
Therapeutic outcome (Table 1) Of the 26 patients, 19 (73.1%) achieved complete remission response rate was 84.6%. Of the 19 patients between 70 and 79 years in age 17 (89.5%) achieved CR. Of the seven patients Adverse effects (Table 2) aged 80 years or over, two (29%) achieved CR. The difference between these two age groups was significant (P Ͻ 0.01). In Adverse effects were rated as grade 0-4 on the WHO criteria. patients having bulky masses у10 cm in diameter, LDH level, Grade 3 or higher hematologic toxicity included leukopenia bone marrow involvement, or a PS of 2-3, the CR rate was in eight patients (30.8%), anemia in three (11.5%), and thromsignificantly lower, but there was no significant difference bocytopenia in two (7.7%). Nausea and vomiting occurred in related to the clinical stage, histological type, extranodular one patient, who recovered rapidly after administration of a site, or phenotype (T cell or B cell).
5-HT3 antagonist. Liver and renal dysfunction, hematuria, constipation, diarrhea, and peripheral neuropathy were all transient. Alopecia resolved within 1-6 months after the comDuration of survival and remission ( Figure 1) pletion of treatment. Grade 2 pulmonary dysfunction in one patient was improved after discontinuation of BLM. Use of a ␤-blocker allowed continuation of THP despite concomitant The 2-year survival rate was 60.3%. Of the 19 patients who achieved CR, 51.4% were disease free 2 years after treatment.
grade 2 arrhythmia in one patient. indication for this regimen. 2 We have previously used COP- incidence of serious adverse effects (particularly severe infections), and thus reported that this combined therapy was safe. 10 COP-BLAM therapy was administered to 36 patients aged 65-79 years. It achieved CR in 32 (88.9%) of the 36 Documented infections patients, with a 4-year survival rate of 60.9%. THP-COPBLM therapy achieved CR in 17 (89.5%) out of 19 patients aged Five (19.2%) of the 26 patients had a temperature у38°C. In 70-79 years; seven patients aged 80 and over were excluded three of the five patients, the elevation was associated with a from this assessment. Consequently, these two regimens were decrease of the granulocyte count to р1000/l. These three not significantly different in efficacy.The WR assessed by patients became afebrile when the granulocyte count was nor-MIBG exceeded 30% when the doses of ADR and THP malized. Upper respiratory infection occurred in one patient, exceeded 250-300 mg/m 2 and 350 mg/m 2 , respectively, sugpneumonia in two, and sepsis in one. Except for the sepsis, gesting the development of cardiac adrenergic dysfunction. Gthese infections were improved by treatment with antibiotics CSF can prevent myelosuppression, permitting the use of high and antifungal agents.
doses of anticancer agents, but other adverse effects may increase as a result of the increased dose intensity. If G-CSF is combined with anthracycline derivatives which produce free
Cardiotoxicity assessed by 123 I-MIBG myocardial radicals, 11 elderly patients will become more susceptible to SPECT ( Figure 2) myocardial damage because their ability to detoxify intracellular free radicals is decreased. We previously measured The LVEF assessed by echocardiography showed no changes the WR, which reflects cardiac sympathetic dysfunction by related to chemotherapy in any patient. The total dose of THP 123 I-MIBG myocardial SPECT in elderly NHL patients who was directly associated with the WR. In particular, the WR received COP-BLAM with G-CSF. This study showed that carincreased when the total dose of THP exceeded 350 mg/m 2 , diac sympathetic dysfunction developed when the dose of suggesting that THP has the potential to cause cardiac DXR exceeded 250-300 mg/m 2 . 12 MIBG is an analog of noresympathetic dysfunction.
pinephrine (NE) and is incorporated into sympathetic nerve terminals by a mechanism similar to that for NE. According to a study in rats by Wakasugi et al, 13 the WR is a useful Discussion biochemical marker for dysfunction of the cardiac sympathetic nervous system and such dysfunction associated with the The incidence of NHL is higher in the elderly than in younger total dose of DXR and the duration of chemotherapy. THP is populations. Although elderly patients with NHL have been a derivative of DXR that has recently been used to treat NHL in elderly patients, because it has less cardiotoxicity and seldom produces alopecia and skin disorders. Kitamura 14 used the THP-COP regimen (THP, CPM, VCR, PDN) to treat NHL in 144 patients aged 65 years and over, and CR was achieved in 45.1%, with a significantly lower incidence of skin disorders such as alopecia when compared with the CHOP regimen. They reported, however, that the white blood cell count decreased to р2000/l in 44.2% of patients receiving THP, which was higher than the rate of 28.5% for the CHOP regimen. In the present study, to cope with leukopenia due to THP, we used G-CSF. In addition, to detect cardiotoxicity, we not only used electrocardiography and echocardiography, but also 123 -MIBG myocardial SPECT. The CR rate of 73.1% and the 2-year survival rate of 60.3% which we achieved were
Figure 2
Relationship between washout rate of 123 I-MIBG and total dose of pirarubicin.
satisfactory if the age of the patients was taken into consider-
